Role of Genes That Modulate Host Immune Responses
http://www.100md.com
病菌学杂志 2005年第10期
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215
Therion Biologics Corporation, Cambridge, Massachusetts 02142
ABSTRACT
Poxvirus vaccine vectors, although capable of eliciting potent immune responses, pose serious health risks in immunosuppressed individuals. We therefore constructed five novel recombinant vaccinia virus vectors which contained overlapping deletions of coding regions for the B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R immunomodulatory gene products and assessed them for both immunogenicity and pathogenicity. All five of these novel vectors elicited both cellular and humoral immunity to the inserted HIV-BH10 env comparable to that induced by the parental Wyeth strain vaccinia virus. However, deletion of these immunomodulatory genes did not increase the immunogenicity of these vectors compared with the parental vaccinia virus. Furthermore, four of these vectors were slightly less virulent and one was slightly more virulent than the Wyeth strain virus in neonatal mice. Attenuated poxviruses have potential use as safer alternatives to current replication-competent vaccinia virus. Improved vaccinia virus vectors can be generated by deleting additional genes to achieve a more significant viral attenuation.
TEXT
Poxviruses are attractive vaccine vectors, due in part to their ability to elicit strong and long-lasting CD4+ and CD8+ T-lymphocyte responses, as well as humoral immune responses (4, 12, 13, 17, 18, 23). However, replication-competent poxvirus vectors pose serious health risks because of their well-documented capacity to disseminate in immunosuppressed individuals (7, 9, 31, 41, 43). These risks have increased in recent years due to a rising proportion of the population living with immunosuppression resulting from human immunodeficiency virus (HIV) infection, organ transplantation, or cancer therapies. Poxviruses are being explored as vectors for vaccines against a variety of diseases, including AIDS and cancer. In addition, widespread public vaccination is being considered to counter the threat of a use of smallpox as a bioterrorist weapon. There is, therefore, a need for safer poxvirus vaccine vectors that are highly immunogenic but have minimal pathogenic potential.
Attenuated and host range-restricted poxviruses that undergo limited replication in human and other mammalian cell lines, such as modified vaccinia virus Ankara (MVA) and canarypox, have been developed as vaccine vectors for use in humans. These poxvirus vectors have been shown to be safe for use in humans (15, 21, 35, 39) and to induce protective immunity in animal models (8, 36, 38) and would therefore appear to represent the poxvirus vectors of choice for human vaccine development. However, the disappointing immunogenicity in human volunteers of the recombinant MVA-HIV vaccine constructs in the recently reported International AIDS Vaccine Initiative trials (W. Jaoko et al., AIDS Vaccines Int. Conf., abstr. 2004) as well as the high-dose recombinant canarypox-HIV administration in the HIV Vaccine Trials Network trials (P. Goepfert et al., 10th Conf. Retrovir. Opportun. Infect., abstr. 82, 2003) suggest that more potent recombinant poxvirus constructs will be needed for the production of an effective HIV vaccine. Therefore, we engineered recombinant vaccinia virus vectors by selectively deleting portions of the vaccinia virus genome in an attempt to create attenuated vectors that retain immunogenicity for use as HIV vaccines.
Recent studies have demonstrated that poxvirus genomes encode a variety of proteins that are associated with immune function. These proteins include homologs of mammalian proteins that are involved in the induction of and/or activity of various immune system components and are thus likely to contribute to the immunosuppressive and pathogenic properties of poxviruses. Moreover, it has been proposed that poxviruses may be made more immunogenic through the deletion of some or all of these immune-related genes (1, 14, 52, 53). To evaluate these hypotheses, we created a series of novel vaccinia viruses through systematic inactivation of vaccinia virus gene products that specifically interact with immune functions. Attractive targets for this strategy included the vaccinia virus genes that encode a gamma interferon (IFN-) receptor (2, 37), serine protease inhibitors (serpins) (10, 27, 29, 48), complement regulators (19, 24, 28), protein kinases (6), and cytokine receptors (1, 11, 47, 49-51).
In the present study, we deleted poxvirus B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R from a Wyeth strain vaccinia virus that contained HIV-1 BH10 env (see Table 1 for a description of deleted genes and their cellular homologs). We then quantified antivector and anti-Env immune responses as well as the pathogenicity of each vector in mice with the hope of identifying new, safer poxvirus constructs that might have utility as vaccine vectors and smallpox vaccines.
Recombinant viral constructs. The recombinant vaccinia virus vT273 expressing HIV-1 BH10 env (gp160) was constructed by inserting the env sequence into a nonessential site in the HindIII M region (16) of the TBC-33 strain of vaccinia virus by in vivo recombination as previously described (33). In the vT273 construct, env expression is controlled by the vaccinia virus 40K (H5R) promoter (22, 42). The control recombinant vaccinia virus vT134 contains no env insertion, but does contain the lacZ gene, and thus can be used as a negative control virus when evaluating Env-associated viral effects.
The deletion mutants vT287, vT285, vT290, vT281, and vT284 were engineered from vT273 to contain a series of gene deletions in the HindIIIB region (Table 1) by replacing the native vaccinia sequences with the Escherichia coli lacZ gene under control of the C1 promoter (26). The deleted gene products included a variety of immunomodulatory proteins, some with homology to serine protease inhibitors (serpins) and the gamma interferon (IFN-) receptor. Deleted genes were located in the B5R-B19R region of the vaccinia virus genome (Table 1). The genomic structure of these recombinant viruses was confirmed by PCR (data not shown).
Expression of Env gp160 by each gene-deleted vaccinia construct was demonstrated by in situ immunostaining using an anti-gp41 antibody (clone Chessie 8; data not shown) and by soluble CD4 enzyme-linked immunosorbent assay. Samples were prepared by infecting 3 x 106 BSC-40 cells with each recombinant viral construct or vaccinia virus vAbT-33 (negative control) at a multiplicity of infection of 10. Following a 24-hour infection, the cells and culture medium were harvested and separated by centrifugation. The culture medium (supernatant) was analyzed for expression levels of Env. The cell pellets were lysed in 0.5 ml of MPER buffer (Pierce Biotechnology, Inc., Rockford, IL), and insoluble debris were pelleted by centrifugation. The resulting supernatant (lysate) was analyzed for Env expression.
The soluble enzyme-linked immunosorbent assay was conducted by coating 96-well plates with 0.05 μg of CD4 (DuPont NEN, Boston, MA). The next day, standards (native HIV-1 IIIB gp120, ABI), and samples (supernatants and lysates) were incubated for 1 h at 37°C. Following the incubation, HIV-1 human serum (Scripps Laboratories, San Diego, CA) biotinylated in-house was added and incubated at 37°C for 1 h, plates were developed using horseradish peroxidase-streptavidin and tetramethylbenzidine microwell substrate (KPL, Inc., Gaithersburg, MD). Vaccinia virus vAbT-33 was used as the negative control in this assay. As shown in Table 2, no major differences in Env gp160 expression levels were detected among the various recombinants.
In vivo immunogenicity. Female BALB/c mice (8 to 10 weeks old; Charles River Laboratories, Cambridge, MA) were maintained in accordance with the guidelines of the Committee on Animals for the Harvard Medical School and the Guide for the Care and Use of Laboratory Animals. Mice were immunized with 50 x 106 PFU of each recombinant vaccinia virus construct (Table 1; n = 4 per group) by the intraperitoneal route on days 0 and 56.
Levels of circulating anti-gp120 and antivector antibodies elicited by each gene-deleted vaccinia virus in the peripheral blood of mice 0 and 4 weeks after the prime inoculation as well as 2 and 15 weeks after the boost inoculation were assessed by enzyme-linked immunosorbent assay (Fig. 1). Anti-gp120 and antivector antibody responses in na?ve animals are not shown, as all absorbances from these serum samples fell below the cutoff used for the determination of antibody titer values in immunized animals. Despite significant modification of the viral genome by deletion of genes previously reported to affect host immune responses, the anti-gp120 and antivector antibody responses detected in each of the experimentally immunized groups were similar to those detected in the mice immunized with the parental vT273 (Fig. 1; exact Wilcoxon rank sum test; all P > 0.1 except as discussed below).
However, the antivector antibody responses detected in the groups immunized with vT281 (B16R-B19R; P = 0.03), vT284 (B8R-B19R; P = 0.03), and vT290 (B5R-B15R; P = 0.02) were lower than the responses detected in mice immunized with vT273 at week 4 postinoculation. This may indicate slower kinetics of the humoral immune response to the vaccinia virus in mice immunized with these vectors compared with the parental vector. Further, the antivector antibody responses detected in the groups immunized with vT281 (B16R-B19R; P = 0.08 at week 2 postboost) and vT284 (B8R-B19R; P = 0.05 at week 2 postboost and P = 0.03 at week 15 postboost) continued to be lower than those detected in mice immunized with the parental vT273 following boost immunization (Fig. 1). Meanwhile, with the exception of mice immunized with vT290 at week 4 postinoculation (P = 0.03), the anti-gp120 antibody responses elicited in all the groups of mice experimentally immunized were comparable to responses elicited in mice immunized with the parental vT273 at all time points assayed.
CD8+ T lymphocytes elicited by each recombinant vaccinia virus construct were assessed (Fig. 2) by tetramer staining followed by flow cytometric analysis of peripheral blood samples. Briefly, red blood cells from approximately 100 μl of whole blood were lysed in a solution of NH4Cl-Tris. Peripheral blood mononuclear cells were then washed and stained with 0.1 to 0.2 μg phycoerythrin (PE)-labeled H-2Dd/p18 tetramer complexes in conjunction with anti-CD8-PE-Cy5 monoclonal antibodies (CT-CD8a; Caltag, Burlingame, CA) as previously described (44). This allowed the detection of CD8+ T lymphocytes that recognize the H-2Dd-restricted dominant p18 epitope (RGPGRAFVTI), derived from the V3 loop of HIV-1 BH10 Env (40, 46). The PE-labeled H-2Dd/p18 tetramer complexes were constructed as described (3, 30). Washed peripheral blood mononuclear cells were fixed in 0.5 ml of phosphate-buffered saline containing 1.5% formaldehyde and analyzed on a Coulter EPICS XL (Beckman Coulter, Fullerton, CA).
The Env-specific CD8+ cellular responses elicited by these viruses were comparable after priming immunization (Fig. 2; exact Wilcoxon rank sum test; all P > 0.1 at days 7 and 49 postinoculation). Following boosting, vT290 (B5R-B15R) only elicited lower levels of CD8+ T lymphocytes (P = 0.03 at days 7 and 53 postboost) compared with mice immunized with the parental vT273 (Fig. 2). Levels of CD8+ T lymphocytes elicited after boost in mice immunized with vT287 (B5R-B8R) were not statistically different (P > 0.1 at days 7 and 53 postboost) than those elicited in mice immunized with the parental vT273 (Fig. 2).
In vivo pathogenicity. Having shown that these gene-deleted viral vectors exhibited little to no loss of immunogenicity (Fig. 1 and 2), we evaluated whether these gene deletions resulted in the attenuation of their pathogenicity. For these studies, weanling BALB/c AnNTac mice (n = 10 per group; Taconic, Germantown, N.Y.) were inoculated intracranially with each recombinant virus (Table 1) in serial dilutions to determine the 50% lethal dose (LD50) over a period of 13 days. All the recombinant viruses were able to kill the mice at the highest dose tested between 3 and 5 days after inoculation. The number of live and dead mice was recorded and the LD50 was determined. The LD50s calculated from one experiment are shown in Table 3. All gene-deleted vectors but vT281 exhibited modestly (<1 log) reduced pathogenicity compared to the parental vT273. Similar results were obtained in a second experiment (data not shown).
A subtle association was seen in this study between the pathogenicity and immunogenicity of these gene-deleted constructs. The lowest LD50 was seen for vT290 (B5R-B15R). This virus elicited cellular anti-Env responses comparable to the wild-type vT273 after a priming immunization. However, after boosting, p18-binding CD8+ cell levels in mice immunized with vT290 were significantly lower than in mice immunized with vT273. Conversely, although lower after priming, humoral responses in mice immunized with vT290 were comparable to those in mice immunized with vT273 after boost. These results, when contrasted with the LD50 and magnitude of immune responses seen in mice inoculated with vT285 (B8R-B15R) that were comparable to those seen following vT273 inoculation, may implicate B5R, a complement activation regulatory protein homolog (19, 20, 24), as a stronger influence on host immune function and vector pathogenicity than are B8R, B12R, B13R, B14R, and B15R. The deletion of immunomodulatory genes in vT290 in addition to B5R may have increased the attenuation of this vector.
The present findings do not support the contention that the immune-related genes carried by vaccinia virus contribute to decreasing the immunogenic properties of the virus. Thus, deletion of B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R gene products does not improve the capacity of vaccinia virus to augment immune responses to a heterologous HIV-1 Env protein carried by the virus. This is perhaps not surprising, since these specific gene deletions do not likely change the kinetics of vaccinia virus replication in vivo or the expression of the heterologous gene. In fact, we have recently shown that vaccinia virus is comparable in its immunogenicity in rhesus macaques to MVA (45), an attenuated vaccinia virus that was derived by over 500 serial passages of the Ankara strain on primary chicken embryo fibroblasts, resulting in multiple genomic deletions totaling approximately 31 kb (5, 34).
The observations in this study also do not argue for a role of these immune-related genes in the pathogenic potential of vaccinia virus. While a reduction in the pathogenicity of selected gene-deleted vaccinia virus constructs was seen in the present experiments, this reduction was modest in magnitude. It is possible that other in vivo assays for pathogenicity might uncover differences between these new vaccinia virus constructs and the wild-type virus. In fact, Legrand et al. (32) have recently reported that nude mice infected with vaccinia viruses with focused serpin-related gene B13R and B22R deletions have a longer survival than nude mice infected with wild-type virus. These same mutants manifested lower virus titers and weight loss in vivo in immunocompetent CB6F1 mice as well (32). In that work, vaccinia virus strain WR was used, which is more pathogenic than the Wyeth strain which has been used in the present study. This may also account for the higher pathogenicity differences observed by Legrand et al. (32). Nevertheless, the present study suggests that any such decrease in pathogenicity may be modest in other vaccinia strains and/or model-dependent.
Why poxviruses have picked up a variety of host genes and continued to carry these genes is not readily apparent. These genes may confer subtle selective advantages for the viruses, but the nature of those advantages is not clear. Continued study of this important vaccine and immunizing vector will be important to improve its immunogenicity and pathogenic profile.
ACKNOWLEDGMENTS
We thank Abe Germansderfer for plasmid generation, Karen F. Gross, James E. Monroe, and Niem T. Nguyen for virus production, and Brianne R. Barker for statistical assistance.
This work was supported by NIH grant AI26507.
REFERENCES
Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.
Alcami, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639.
Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
Amara, R. R., P. Nigam, S. Sharma, J. Liu, and V. Bostik. 2004. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J. Virol. 78:3811-3816.
Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
Banham, A. H., and G. L. Smith. 1993. Characterization of vaccinia virus gene B12R. J. Gen. Virol. 74:2807-2812.
Baxby, D. 1991. Safety of recombinant vaccinia vaccines. Lancet 337:913.
Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100:9458-9463.
Booss, J., and L. E. Davis. 2003. Smallpox and smallpox vaccination: neurological implications. Neurology 60:1241-1245.
Boursnell, M. E., I. J. Foulds, J. I. Campbell, and M. M. Binns. 1988. Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. J. Gen. Virol. 69:2995-3003.
Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:15974-15978.
Combadiere, B., A. Boissonnas, G. Carcelain, E. Lefranc, A. Samri, F. Bricaire, P. Debre, and B. Autran. 2004. Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-{gamma}-producing T Cell Memory to Smallpox in Humans. J. Exp. Med. 199:1585-1593.
Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
Dallo, S., J. S. Maa, J. R. Rodriguez, D. Rodriguez, and M. Esteban. 1989. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173:323-329.
de Bruyn, G., A. J. Rossini, Y. L. Chiu, D. Holman, M. L. Elizaga, S. E. Frey, D. Burke, T. G. Evans, L. Corey, and M. C. Keefer. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-713.
DeFilippes, F. M. 1982. Restriction enzyme mapping of vaccinia virus DNA. J. Virol. 43:136-149.
Demkowicz, W. E., Jr., R. A. Littaua, J. Wang, and F. A. Ennis. 1996. Hum. cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70:2627-2631.
Eichner, M. 2003. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am. J. Epidemiol. 158:717-723.
Engelstad, M., S. T. Howard, and G. L. Smith. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801-810.
Engelstad, M., and G. L. Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-637.
Gilbert, P. B., Y. L. Chiu, M. Allen, D. N. Lawrence, C. Chapdu, H. Israel, D. Holman, M. C. Keefer, M. Wolff, and S. E. Frey. 2003. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-2947.
Gritz, L., A. Destree, N. Cormier, E. Day, V. Stallard, T. Caiazzo, G. Mazzara, and D. Panicali. 1990. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol. 64:5948-5957.
Harrington, L. E., R. Most Rv, J. L. Whitton, and R. Ahmed. 2002. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:3329-3337.
Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89:628-632.
Isaacs, S. N., E. J. Wolffe, L. G. Payne, and B. Moss. 1992. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:7217-7224.
Jenkins, S., L. Gritz, C. H. Fedor, E. M. O'Neill, L. K. Cohen, and D. L. Panicali. 1991. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses. 7:991-998.
Kettle, S., N. W. Blake, K. M. Law, and G. L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206:136-147.
Kotwal, G. J., and B. Moss. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-178.
Kotwal, G. J., and B. Moss. 1989. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J. Virol. 63:600-606.
Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373-1381.
Lane, J. M., and J. Goldstein. 2003. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med. 138:488-493.
Legrand, F. A., P. H. Verardi, L. A. Jones, K. S. Chan, Y. Peng, and T. D. Yilma. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779.
Mazzara, G. P., A. Destree, and A. Mahr. 1993. Generation and analysis of vaccinia virus recombinants. Methods Enzymol. 217:557-581.
Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med Biol. 397:7-13.
Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.
Ourmanov, I., C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
Rosel, J. L., P. L. Earl, J. P. Weir, and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol. 60:436-449.
Rosenthal, S. R., M. Merchlinsky, C. Kleppinger, and K. L. Goldenthal. 2001. Developing new smallpox vaccines. Emerg. Infect. Dis. 7:920-926.
Santra, S., D. H. Barouch, S. S. Jackson, M. J. Kuroda, J. E. Schmitz, M. A. Lifton, A. H. Sharpe, and N. L. Letvin. 2000. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J. Immunol. 165:6791-6795.
Santra, S., D. H. Barouch, B. Korioth-Schmitz, C. I. Lord, G. R. Krivulka, F. Yu, M. H. Beddall, D. A. Gorgone, M. A. Lifton, A. Miura, V. Philippon, K. Manson, P. D. Markham, J. Parrish, M. J. Kuroda, J. E. Schmitz, R. S. Gelman, J. W. Shiver, D. C. Montefiori, D. Panicali, and N. L. Letvin. 2004. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA 101:11088-11093.
Shirai, M., K. Kurokohchi, C. D. Pendleton, T. Arichi, L. F. Boyd, H. Takahashi, D. H. Margulies, and J. A. Berzofsky. 1996. Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160. J. Immunol. 157:4399-4411.
Smith, G. L., and Y. S. Chan. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:511-518.
Smith, G. L., S. T. Howard, and Y. S. Chan. 1989. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J. Gen. Virol. 70:2333-2343.
Spriggs, M. K., D. E. Hruby, C. R. Maliszewski, D. J. Pickup, J. E. Sims, R. M. Buller, and J. VanSlyke. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-152.
Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
Ueda, Y., S. Morikawa, and Y. Matsuura. 1990. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology 177:588-594.
Verardi, P. H., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 2001. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J. Virol. 75:11-18.
Zhou, J., L. Crawford, L. McLean, X. Y. Sun, M. Stanley, N. Almond, and G. L. Smith. 1990. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J. Gen. Virol. 71:2185-2190.(Shawn S. Jackson, Petr Il)
Therion Biologics Corporation, Cambridge, Massachusetts 02142
ABSTRACT
Poxvirus vaccine vectors, although capable of eliciting potent immune responses, pose serious health risks in immunosuppressed individuals. We therefore constructed five novel recombinant vaccinia virus vectors which contained overlapping deletions of coding regions for the B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R immunomodulatory gene products and assessed them for both immunogenicity and pathogenicity. All five of these novel vectors elicited both cellular and humoral immunity to the inserted HIV-BH10 env comparable to that induced by the parental Wyeth strain vaccinia virus. However, deletion of these immunomodulatory genes did not increase the immunogenicity of these vectors compared with the parental vaccinia virus. Furthermore, four of these vectors were slightly less virulent and one was slightly more virulent than the Wyeth strain virus in neonatal mice. Attenuated poxviruses have potential use as safer alternatives to current replication-competent vaccinia virus. Improved vaccinia virus vectors can be generated by deleting additional genes to achieve a more significant viral attenuation.
TEXT
Poxviruses are attractive vaccine vectors, due in part to their ability to elicit strong and long-lasting CD4+ and CD8+ T-lymphocyte responses, as well as humoral immune responses (4, 12, 13, 17, 18, 23). However, replication-competent poxvirus vectors pose serious health risks because of their well-documented capacity to disseminate in immunosuppressed individuals (7, 9, 31, 41, 43). These risks have increased in recent years due to a rising proportion of the population living with immunosuppression resulting from human immunodeficiency virus (HIV) infection, organ transplantation, or cancer therapies. Poxviruses are being explored as vectors for vaccines against a variety of diseases, including AIDS and cancer. In addition, widespread public vaccination is being considered to counter the threat of a use of smallpox as a bioterrorist weapon. There is, therefore, a need for safer poxvirus vaccine vectors that are highly immunogenic but have minimal pathogenic potential.
Attenuated and host range-restricted poxviruses that undergo limited replication in human and other mammalian cell lines, such as modified vaccinia virus Ankara (MVA) and canarypox, have been developed as vaccine vectors for use in humans. These poxvirus vectors have been shown to be safe for use in humans (15, 21, 35, 39) and to induce protective immunity in animal models (8, 36, 38) and would therefore appear to represent the poxvirus vectors of choice for human vaccine development. However, the disappointing immunogenicity in human volunteers of the recombinant MVA-HIV vaccine constructs in the recently reported International AIDS Vaccine Initiative trials (W. Jaoko et al., AIDS Vaccines Int. Conf., abstr. 2004) as well as the high-dose recombinant canarypox-HIV administration in the HIV Vaccine Trials Network trials (P. Goepfert et al., 10th Conf. Retrovir. Opportun. Infect., abstr. 82, 2003) suggest that more potent recombinant poxvirus constructs will be needed for the production of an effective HIV vaccine. Therefore, we engineered recombinant vaccinia virus vectors by selectively deleting portions of the vaccinia virus genome in an attempt to create attenuated vectors that retain immunogenicity for use as HIV vaccines.
Recent studies have demonstrated that poxvirus genomes encode a variety of proteins that are associated with immune function. These proteins include homologs of mammalian proteins that are involved in the induction of and/or activity of various immune system components and are thus likely to contribute to the immunosuppressive and pathogenic properties of poxviruses. Moreover, it has been proposed that poxviruses may be made more immunogenic through the deletion of some or all of these immune-related genes (1, 14, 52, 53). To evaluate these hypotheses, we created a series of novel vaccinia viruses through systematic inactivation of vaccinia virus gene products that specifically interact with immune functions. Attractive targets for this strategy included the vaccinia virus genes that encode a gamma interferon (IFN-) receptor (2, 37), serine protease inhibitors (serpins) (10, 27, 29, 48), complement regulators (19, 24, 28), protein kinases (6), and cytokine receptors (1, 11, 47, 49-51).
In the present study, we deleted poxvirus B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R from a Wyeth strain vaccinia virus that contained HIV-1 BH10 env (see Table 1 for a description of deleted genes and their cellular homologs). We then quantified antivector and anti-Env immune responses as well as the pathogenicity of each vector in mice with the hope of identifying new, safer poxvirus constructs that might have utility as vaccine vectors and smallpox vaccines.
Recombinant viral constructs. The recombinant vaccinia virus vT273 expressing HIV-1 BH10 env (gp160) was constructed by inserting the env sequence into a nonessential site in the HindIII M region (16) of the TBC-33 strain of vaccinia virus by in vivo recombination as previously described (33). In the vT273 construct, env expression is controlled by the vaccinia virus 40K (H5R) promoter (22, 42). The control recombinant vaccinia virus vT134 contains no env insertion, but does contain the lacZ gene, and thus can be used as a negative control virus when evaluating Env-associated viral effects.
The deletion mutants vT287, vT285, vT290, vT281, and vT284 were engineered from vT273 to contain a series of gene deletions in the HindIIIB region (Table 1) by replacing the native vaccinia sequences with the Escherichia coli lacZ gene under control of the C1 promoter (26). The deleted gene products included a variety of immunomodulatory proteins, some with homology to serine protease inhibitors (serpins) and the gamma interferon (IFN-) receptor. Deleted genes were located in the B5R-B19R region of the vaccinia virus genome (Table 1). The genomic structure of these recombinant viruses was confirmed by PCR (data not shown).
Expression of Env gp160 by each gene-deleted vaccinia construct was demonstrated by in situ immunostaining using an anti-gp41 antibody (clone Chessie 8; data not shown) and by soluble CD4 enzyme-linked immunosorbent assay. Samples were prepared by infecting 3 x 106 BSC-40 cells with each recombinant viral construct or vaccinia virus vAbT-33 (negative control) at a multiplicity of infection of 10. Following a 24-hour infection, the cells and culture medium were harvested and separated by centrifugation. The culture medium (supernatant) was analyzed for expression levels of Env. The cell pellets were lysed in 0.5 ml of MPER buffer (Pierce Biotechnology, Inc., Rockford, IL), and insoluble debris were pelleted by centrifugation. The resulting supernatant (lysate) was analyzed for Env expression.
The soluble enzyme-linked immunosorbent assay was conducted by coating 96-well plates with 0.05 μg of CD4 (DuPont NEN, Boston, MA). The next day, standards (native HIV-1 IIIB gp120, ABI), and samples (supernatants and lysates) were incubated for 1 h at 37°C. Following the incubation, HIV-1 human serum (Scripps Laboratories, San Diego, CA) biotinylated in-house was added and incubated at 37°C for 1 h, plates were developed using horseradish peroxidase-streptavidin and tetramethylbenzidine microwell substrate (KPL, Inc., Gaithersburg, MD). Vaccinia virus vAbT-33 was used as the negative control in this assay. As shown in Table 2, no major differences in Env gp160 expression levels were detected among the various recombinants.
In vivo immunogenicity. Female BALB/c mice (8 to 10 weeks old; Charles River Laboratories, Cambridge, MA) were maintained in accordance with the guidelines of the Committee on Animals for the Harvard Medical School and the Guide for the Care and Use of Laboratory Animals. Mice were immunized with 50 x 106 PFU of each recombinant vaccinia virus construct (Table 1; n = 4 per group) by the intraperitoneal route on days 0 and 56.
Levels of circulating anti-gp120 and antivector antibodies elicited by each gene-deleted vaccinia virus in the peripheral blood of mice 0 and 4 weeks after the prime inoculation as well as 2 and 15 weeks after the boost inoculation were assessed by enzyme-linked immunosorbent assay (Fig. 1). Anti-gp120 and antivector antibody responses in na?ve animals are not shown, as all absorbances from these serum samples fell below the cutoff used for the determination of antibody titer values in immunized animals. Despite significant modification of the viral genome by deletion of genes previously reported to affect host immune responses, the anti-gp120 and antivector antibody responses detected in each of the experimentally immunized groups were similar to those detected in the mice immunized with the parental vT273 (Fig. 1; exact Wilcoxon rank sum test; all P > 0.1 except as discussed below).
However, the antivector antibody responses detected in the groups immunized with vT281 (B16R-B19R; P = 0.03), vT284 (B8R-B19R; P = 0.03), and vT290 (B5R-B15R; P = 0.02) were lower than the responses detected in mice immunized with vT273 at week 4 postinoculation. This may indicate slower kinetics of the humoral immune response to the vaccinia virus in mice immunized with these vectors compared with the parental vector. Further, the antivector antibody responses detected in the groups immunized with vT281 (B16R-B19R; P = 0.08 at week 2 postboost) and vT284 (B8R-B19R; P = 0.05 at week 2 postboost and P = 0.03 at week 15 postboost) continued to be lower than those detected in mice immunized with the parental vT273 following boost immunization (Fig. 1). Meanwhile, with the exception of mice immunized with vT290 at week 4 postinoculation (P = 0.03), the anti-gp120 antibody responses elicited in all the groups of mice experimentally immunized were comparable to responses elicited in mice immunized with the parental vT273 at all time points assayed.
CD8+ T lymphocytes elicited by each recombinant vaccinia virus construct were assessed (Fig. 2) by tetramer staining followed by flow cytometric analysis of peripheral blood samples. Briefly, red blood cells from approximately 100 μl of whole blood were lysed in a solution of NH4Cl-Tris. Peripheral blood mononuclear cells were then washed and stained with 0.1 to 0.2 μg phycoerythrin (PE)-labeled H-2Dd/p18 tetramer complexes in conjunction with anti-CD8-PE-Cy5 monoclonal antibodies (CT-CD8a; Caltag, Burlingame, CA) as previously described (44). This allowed the detection of CD8+ T lymphocytes that recognize the H-2Dd-restricted dominant p18 epitope (RGPGRAFVTI), derived from the V3 loop of HIV-1 BH10 Env (40, 46). The PE-labeled H-2Dd/p18 tetramer complexes were constructed as described (3, 30). Washed peripheral blood mononuclear cells were fixed in 0.5 ml of phosphate-buffered saline containing 1.5% formaldehyde and analyzed on a Coulter EPICS XL (Beckman Coulter, Fullerton, CA).
The Env-specific CD8+ cellular responses elicited by these viruses were comparable after priming immunization (Fig. 2; exact Wilcoxon rank sum test; all P > 0.1 at days 7 and 49 postinoculation). Following boosting, vT290 (B5R-B15R) only elicited lower levels of CD8+ T lymphocytes (P = 0.03 at days 7 and 53 postboost) compared with mice immunized with the parental vT273 (Fig. 2). Levels of CD8+ T lymphocytes elicited after boost in mice immunized with vT287 (B5R-B8R) were not statistically different (P > 0.1 at days 7 and 53 postboost) than those elicited in mice immunized with the parental vT273 (Fig. 2).
In vivo pathogenicity. Having shown that these gene-deleted viral vectors exhibited little to no loss of immunogenicity (Fig. 1 and 2), we evaluated whether these gene deletions resulted in the attenuation of their pathogenicity. For these studies, weanling BALB/c AnNTac mice (n = 10 per group; Taconic, Germantown, N.Y.) were inoculated intracranially with each recombinant virus (Table 1) in serial dilutions to determine the 50% lethal dose (LD50) over a period of 13 days. All the recombinant viruses were able to kill the mice at the highest dose tested between 3 and 5 days after inoculation. The number of live and dead mice was recorded and the LD50 was determined. The LD50s calculated from one experiment are shown in Table 3. All gene-deleted vectors but vT281 exhibited modestly (<1 log) reduced pathogenicity compared to the parental vT273. Similar results were obtained in a second experiment (data not shown).
A subtle association was seen in this study between the pathogenicity and immunogenicity of these gene-deleted constructs. The lowest LD50 was seen for vT290 (B5R-B15R). This virus elicited cellular anti-Env responses comparable to the wild-type vT273 after a priming immunization. However, after boosting, p18-binding CD8+ cell levels in mice immunized with vT290 were significantly lower than in mice immunized with vT273. Conversely, although lower after priming, humoral responses in mice immunized with vT290 were comparable to those in mice immunized with vT273 after boost. These results, when contrasted with the LD50 and magnitude of immune responses seen in mice inoculated with vT285 (B8R-B15R) that were comparable to those seen following vT273 inoculation, may implicate B5R, a complement activation regulatory protein homolog (19, 20, 24), as a stronger influence on host immune function and vector pathogenicity than are B8R, B12R, B13R, B14R, and B15R. The deletion of immunomodulatory genes in vT290 in addition to B5R may have increased the attenuation of this vector.
The present findings do not support the contention that the immune-related genes carried by vaccinia virus contribute to decreasing the immunogenic properties of the virus. Thus, deletion of B5R, B8R, B12R, B13R, B14R, B16R, B18R, and B19R gene products does not improve the capacity of vaccinia virus to augment immune responses to a heterologous HIV-1 Env protein carried by the virus. This is perhaps not surprising, since these specific gene deletions do not likely change the kinetics of vaccinia virus replication in vivo or the expression of the heterologous gene. In fact, we have recently shown that vaccinia virus is comparable in its immunogenicity in rhesus macaques to MVA (45), an attenuated vaccinia virus that was derived by over 500 serial passages of the Ankara strain on primary chicken embryo fibroblasts, resulting in multiple genomic deletions totaling approximately 31 kb (5, 34).
The observations in this study also do not argue for a role of these immune-related genes in the pathogenic potential of vaccinia virus. While a reduction in the pathogenicity of selected gene-deleted vaccinia virus constructs was seen in the present experiments, this reduction was modest in magnitude. It is possible that other in vivo assays for pathogenicity might uncover differences between these new vaccinia virus constructs and the wild-type virus. In fact, Legrand et al. (32) have recently reported that nude mice infected with vaccinia viruses with focused serpin-related gene B13R and B22R deletions have a longer survival than nude mice infected with wild-type virus. These same mutants manifested lower virus titers and weight loss in vivo in immunocompetent CB6F1 mice as well (32). In that work, vaccinia virus strain WR was used, which is more pathogenic than the Wyeth strain which has been used in the present study. This may also account for the higher pathogenicity differences observed by Legrand et al. (32). Nevertheless, the present study suggests that any such decrease in pathogenicity may be modest in other vaccinia strains and/or model-dependent.
Why poxviruses have picked up a variety of host genes and continued to carry these genes is not readily apparent. These genes may confer subtle selective advantages for the viruses, but the nature of those advantages is not clear. Continued study of this important vaccine and immunizing vector will be important to improve its immunogenicity and pathogenic profile.
ACKNOWLEDGMENTS
We thank Abe Germansderfer for plasmid generation, Karen F. Gross, James E. Monroe, and Niem T. Nguyen for virus production, and Brianne R. Barker for statistical assistance.
This work was supported by NIH grant AI26507.
REFERENCES
Alcami, A., and G. L. Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-167.
Alcami, A., and G. L. Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-4639.
Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
Amara, R. R., P. Nigam, S. Sharma, J. Liu, and V. Bostik. 2004. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J. Virol. 78:3811-3816.
Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
Banham, A. H., and G. L. Smith. 1993. Characterization of vaccinia virus gene B12R. J. Gen. Virol. 74:2807-2812.
Baxby, D. 1991. Safety of recombinant vaccinia vaccines. Lancet 337:913.
Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100:9458-9463.
Booss, J., and L. E. Davis. 2003. Smallpox and smallpox vaccination: neurological implications. Neurology 60:1241-1245.
Boursnell, M. E., I. J. Foulds, J. I. Campbell, and M. M. Binns. 1988. Non-essential genes in the vaccinia virus HindIII K fragment: a gene related to serine protease inhibitors and a gene related to the 37K vaccinia virus major envelope antigen. J. Gen. Virol. 69:2995-3003.
Colamonici, O. R., P. Domanski, S. M. Sweitzer, A. Larner, and R. M. Buller. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem. 270:15974-15978.
Combadiere, B., A. Boissonnas, G. Carcelain, E. Lefranc, A. Samri, F. Bricaire, P. Debre, and B. Autran. 2004. Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-{gamma}-producing T Cell Memory to Smallpox in Humans. J. Exp. Med. 199:1585-1593.
Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973.
Dallo, S., J. S. Maa, J. R. Rodriguez, D. Rodriguez, and M. Esteban. 1989. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173:323-329.
de Bruyn, G., A. J. Rossini, Y. L. Chiu, D. Holman, M. L. Elizaga, S. E. Frey, D. Burke, T. G. Evans, L. Corey, and M. C. Keefer. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-713.
DeFilippes, F. M. 1982. Restriction enzyme mapping of vaccinia virus DNA. J. Virol. 43:136-149.
Demkowicz, W. E., Jr., R. A. Littaua, J. Wang, and F. A. Ennis. 1996. Hum. cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70:2627-2631.
Eichner, M. 2003. Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am. J. Epidemiol. 158:717-723.
Engelstad, M., S. T. Howard, and G. L. Smith. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801-810.
Engelstad, M., and G. L. Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-637.
Gilbert, P. B., Y. L. Chiu, M. Allen, D. N. Lawrence, C. Chapdu, H. Israel, D. Holman, M. C. Keefer, M. Wolff, and S. E. Frey. 2003. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-2947.
Gritz, L., A. Destree, N. Cormier, E. Day, V. Stallard, T. Caiazzo, G. Mazzara, and D. Panicali. 1990. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol. 64:5948-5957.
Harrington, L. E., R. Most Rv, J. L. Whitton, and R. Ahmed. 2002. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:3329-3337.
Isaacs, S. N., G. J. Kotwal, and B. Moss. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89:628-632.
Isaacs, S. N., E. J. Wolffe, L. G. Payne, and B. Moss. 1992. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:7217-7224.
Jenkins, S., L. Gritz, C. H. Fedor, E. M. O'Neill, L. K. Cohen, and D. L. Panicali. 1991. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses. 7:991-998.
Kettle, S., N. W. Blake, K. M. Law, and G. L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology 206:136-147.
Kotwal, G. J., and B. Moss. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-178.
Kotwal, G. J., and B. Moss. 1989. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J. Virol. 63:600-606.
Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373-1381.
Lane, J. M., and J. Goldstein. 2003. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med. 138:488-493.
Legrand, F. A., P. H. Verardi, L. A. Jones, K. S. Chan, Y. Peng, and T. D. Yilma. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779.
Mazzara, G. P., A. Destree, and A. Mahr. 1993. Generation and analysis of vaccinia virus recombinants. Methods Enzymol. 217:557-581.
Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. M. Hirsch, S. Goldstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med Biol. 397:7-13.
Mossman, K., C. Upton, R. M. Buller, and G. McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-769.
Ourmanov, I., C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
Rosel, J. L., P. L. Earl, J. P. Weir, and B. Moss. 1986. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J. Virol. 60:436-449.
Rosenthal, S. R., M. Merchlinsky, C. Kleppinger, and K. L. Goldenthal. 2001. Developing new smallpox vaccines. Emerg. Infect. Dis. 7:920-926.
Santra, S., D. H. Barouch, S. S. Jackson, M. J. Kuroda, J. E. Schmitz, M. A. Lifton, A. H. Sharpe, and N. L. Letvin. 2000. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J. Immunol. 165:6791-6795.
Santra, S., D. H. Barouch, B. Korioth-Schmitz, C. I. Lord, G. R. Krivulka, F. Yu, M. H. Beddall, D. A. Gorgone, M. A. Lifton, A. Miura, V. Philippon, K. Manson, P. D. Markham, J. Parrish, M. J. Kuroda, J. E. Schmitz, R. S. Gelman, J. W. Shiver, D. C. Montefiori, D. Panicali, and N. L. Letvin. 2004. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA 101:11088-11093.
Shirai, M., K. Kurokohchi, C. D. Pendleton, T. Arichi, L. F. Boyd, H. Takahashi, D. H. Margulies, and J. A. Berzofsky. 1996. Reciprocal cytotoxic T lymphocyte cross-reactivity interactions between two major epitopes within HIV-1 gp160. J. Immunol. 157:4399-4411.
Smith, G. L., and Y. S. Chan. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:511-518.
Smith, G. L., S. T. Howard, and Y. S. Chan. 1989. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J. Gen. Virol. 70:2333-2343.
Spriggs, M. K., D. E. Hruby, C. R. Maliszewski, D. J. Pickup, J. E. Sims, R. M. Buller, and J. VanSlyke. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-152.
Symons, J. A., A. Alcami, and G. L. Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-560.
Ueda, Y., S. Morikawa, and Y. Matsuura. 1990. Identification and nucleotide sequence of the gene encoding a surface antigen induced by vaccinia virus. Virology 177:588-594.
Verardi, P. H., L. A. Jones, F. H. Aziz, S. Ahmad, and T. D. Yilma. 2001. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity. J. Virol. 75:11-18.
Zhou, J., L. Crawford, L. McLean, X. Y. Sun, M. Stanley, N. Almond, and G. L. Smith. 1990. Increased antibody responses to human papillomavirus type 16 L1 protein expressed by recombinant vaccinia virus lacking serine protease inhibitor genes. J. Gen. Virol. 71:2185-2190.(Shawn S. Jackson, Petr Il)